Page 31 - Recursion Pharmaceuticals News Today

Stocks rose overnight after new data raised hope that the Federal Reserve can bring down inflation without pushing the US economy into a recession. The consumer price index rose 3 per...

NVIDIA Corporation (NASDAQ:NVDA) has dedicated US$50mln to a multi-year collaboration with US-listed biotech company Recursion Pharmaceuticals to develop...

Key Insights Recursion Pharmaceuticals' estimated fair value is US$14.64 based on 2 Stage Free Cash Flow to Equity...

(CTN News) - Nvidia, a leading chipmaker, has announced a $50 million investment in Recursion Pharmaceuticals, a biotech firm that uses artificial

Recursion has a library of 3 trillion searchable genes that will serve as the foundation for the company's AI-powered drug discovery program.

Shares of Recursion Pharmaceuticals, Inc. (RXRX) are trading down on Thursday morning after surging to a year-to-date high on yesterday after announcing a collaboration and $50 million investment by Nvidia as a private investment in public equity.

ISTANBUL US chipmaker Nvidia invested $50 million in Recursion Pharmaceuticals to accelerate models in artificial intelligence (AI) enabled drug discovery. Recursion said Wednesday in a

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) shares are trading lower on Thursday as traders appear to be taking profits. The stock rallied on Wednesday after the company announced a $50 m

Nvidia (NVDA) stock rose 1.25% in Thursday’s premarket to $444.50 – a new all-time high – although the advance is sagging as the opening bell nears.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips RXRX stock is the talk of Wall Street today after Recursion Pharmaceuticals shot up 100% on a…